Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties... Show more
A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To RPRX | 1D Price Change % | ||
|---|---|---|---|---|
| RPRX | 100% | +4.28% | ||
| AXON - RPRX | 48% Loosely correlated | -1.19% | ||
| INCY - RPRX | 46% Loosely correlated | +2.72% | ||
| VRTX - RPRX | 46% Loosely correlated | +2.74% | ||
| RIGL - RPRX | 41% Loosely correlated | -0.68% | ||
| EXEL - RPRX | 38% Loosely correlated | +2.49% | ||
More | ||||
a provider of drug development services
Industry Biotechnology
The Aroon Indicator for RPRX entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 147 similar instances where the Aroon Indicator formed such a pattern. In 101 of the 147 cases the stock moved lower. This puts the odds of a downward move at 69%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
RPRX moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RPRX crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RPRX's RSI Indicator exited the oversold zone, 17 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 49 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 30 of 52 cases over the following month. The odds of a continued upward trend are 58%.
Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 177 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
RPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.804) is normal, around the industry mean (26.782). P/E Ratio (31.382) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). RPRX's Dividend Yield (0.016) is considerably higher than the industry average of (0.000). P/S Ratio (12.870) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 31 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.